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Vitamin D plays a pivotal role in almost all the organ systems of the human body. Vitamin D deficiency (VDD) is considered as an epidemic in India. The prevalence 
of VDD is highly variable and is reported to range from 34% 
to 70–100% in different Indian studies [1]. It is known that the 
prevalence of VDD varies with several factors such as age, sex, 
season, geographic region, sunlight exposure, and dietary intake. 
With the decreasing number of new infections and expanding 
accessibility to antiretroviral therapy (ART), the life span of 
children living with HIV (CLHIV) is prolonged [2]. VDD in HIV 
patients has been associated with immunological hyper-reactivity, 
advanced clinical HIV infection, and increased mortality [3-5].
Globally, various studies have assessed the prevalence of VDD 
in HIV positive adults, but there are a limited number of studies in 
children [6-9]. Moreover, studies from the Indian subcontinent are 
sparse. The present study was planned in the pediatric HIV center 
of a tertiary care teaching hospital of Northern Indian to assess the 
prevalence of VDD in CLHIV and to compare it with age- and sex-
matched healthy controls and to find out the associated risk factors.
MATERIALS AND METHODS
This cross-sectional study was carried out in a tertiary care 
teaching institution from November 2013 to March 2015 
after obtaining Institutional Review Board clearance. A total 
of 52 CLHIV under the age of 18 years were consecutively 
enrolled from the pediatric HIV clinic and an equal number 
of age- and sex-matched healthy controls were enrolled from 
the outpatient department of the hospital. A written informed 
consent was obtained from the parents/guardians. Children who 
were on systemic steroids, antiepileptic drugs, Vitamin D, or 
calcium supplements or suffering from kidney (serum creatinine 
>2 mg/dL) or liver disease (ALT >100 IU/L) were excluded 
from the study.
The age, sex, height, weight, body mass index (BMI), age at 
diagnosis, the WHO stage, route of transmission, and treatment 
details were recorded for all the subjects enrolled. Anthropometry 
was interpreted using BMI Z-scores as per the WHO guidelines 
as obesity with more than +2SD, thinness as <−2SD, and normal 
between +2SD and −2SD. Daily calcium and Vitamin D intake 
were calculated taking the average of 3 days by the recall 
method using locally available charts depicting the calcium and 
Vitamin D content of commonly eaten North Indian food items. 
Daily sunlight exposure was calculated by asking the parent/
guardian to recall the number of hours spent by the child in the 
open under sunlight in a whole day, considering the child’s daily 
activities and the child’s clothing pattern. The exposure was 
expressed as the surface area of body parts directly exposed to 
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sunlight multiplied by the number of units, for which these parts 
were exposed in the whole day (min*m2/day).
Venous blood was analyzed for Vitamin D, parathormone, 
calcium, phosphorus, alkaline phosphatase level, liver and 
kidney function tests, serum electrolytes, and complete blood 
counts. Serum 25-OH Vitamin D levels were estimated by 
chemiluminescence immunoassay technique and graded as per 
the Endocrine Society Clinical Practice Guidelines published in 
2011. These were divided into VDD (<20 ng/mL), insufficiency 
(VDI) (21–29 ng/mL), and sufficiency (VDS) (>30 ng/mL) [10]. 
The normal reference ranges for other laboratory parameters 
were serum parathyroid hormone (PTH) (<65 pg/mL), calcium 
(8.6–10.3 mg/dL), phosphorus (4.0–7.0 mg/dL), and alkaline 
phosphatase (100–390 µ/L for males and 100–320 µ/L for 
females).
The sample size was calculated as 52 in both the groups on 
the basis of a similar study done by Meyzer et al. to detect a 
mean difference in Vitamin D level of 3.8 ng/ml between controls 
(14.2 ng/ml) and cases (10.4 ng/ml), with a standard deviation of 
6.9 ng/ml in the control group and 5 ng/ml in cases, considering 
two-sided alpha of 0.05 and power of 80% [11].
Statistical testing was conducted with the SPSS version 21.0. 
The comparison of continuous variables between the groups 
was performed using Student’s t-test. Nominal categorical data 
were compared using Chi-square test or Fisher’s exact test as 
appropriate. Non-normally distributed continuous variables 
were compared using Mann–Whitney U-test. Univariate analysis 
followed by multivariate logistic regression was performed for 
analyzing the risk factors for VDD in CLHIV. For all statistical 
tests, p<0.05 was considered as statistically significant.
RESULTS
This study compared 52 CLHIV (mean age = 10.19±3.35 years) 
and 52 healthy controls (mean age = 9.64±3.14 years). The male-
to-female ratio was 1.89. Comparison of the BMI revealed a 
significantly lower proportion of nutritionally normal subjects 
in the HIV-infected group (32/52, 61.54%) in comparison to 
controls (48/52, 92.31%) (p=0.001). Other subjects were either 
thin (34.62% of cases and 7.69% of controls) or obese (3.85% of 
cases and 0% of controls).
Table 1 depicts the comparative profile of the two groups. 
Daily intake of Vitamin D and daily sunlight exposure in CLHIV 
were significantly lower in comparison to the controls. Similarly, 
serum Vitamin D and serum phosphorus levels were significantly 
lower in cases than controls, while the serum PTH levels were 
significantly higher for cases than controls.
Assessment of Vitamin D levels revealed that 69.23% of cases 
and 19.23% of controls had VDD; 17.31% of cases and 32.69% 
of controls had VDI; and 13.46% of cases and 48.08% of controls 
had VDS. The difference was statistically significant between the 
two study groups (p<0.001). Chi-square test was used to analyze 
the association between Vitamin D statuses of the HIV cases with 
different risk factors (Table 2). The factors that were significantly 
associated with Vitamin D status were WHO stage (p=0.04) and 
average Vitamin D intake (p<0.005). Correlation analysis did not 
reveal any significant correlation between Vitamin D level and 
CD4 count (r=0.023, 95% CI=−0.25–0.29, p=0.87).
Risk assessment was done for VDD in cases for both the 
classical and disease-specific risk factors, namely, age, sex, BMI, 
average intake of calcium and Vitamin D, sunlight exposure, 
immunological and WHO stage, duration of treatment, and 
regimen which were evaluated by logistic regression. The factors 
which significantly predicted VDD by univariate analysis were 
average intake of calcium, average intake of Vitamin D (p<0.001), 
and WHO stage (p=0.01). Multivariate analysis revealed that only 
a lower average intake of Vitamin D predicted VDD (p=0.002).
DISCUSSION
Vitamin D plays an important part in the immune system and its 
deficiency is also implicated in the progression of HIV [12,13]. 
The absence of routine Vitamin D supplementation can interfere 
with the peak bone mass acquisition and could lead to an increased 
risk of low bone mineral density in these vulnerable children [14]. 
The present study observed a high prevalence of VDD in CLHIV 
(69.23%) in comparison to age- and sex-matched healthy controls 
(19.23%). Few previous studies carried out in other parts of the 
world also assessed the prevalence of VDD in CLHIV [11,15-20]. 
A study carried out in perinatally infected Thai adolescents aged 
12–20 years, on long-term ART, observed a comparatively lower 
prevalence of VDD (24.7%) [18].
Another study published by Meyzer et al. carried out in HIV-
infected children (≤24 years) who reported the frequency of VDD to 
be 38.9% [11]. Rutstein et al. reported the prevalence of VDD as 36% 
in perinatally HIV-infected children [16]. The high frequency of VDD 
in the present study could be due to the different ethnic backgrounds, 
Table 1: Comparison of different parameters among cases 
(CLHIV) and controls
Variable (unit) Cases 
(Mean±SD)
Controls 
(Mean±SD)
p-value
Weight (kg) 26.18±6.60 30.06±11.05 0.03
Height (cm) 129.18±15.59 133.22±18.09 0.23
Average intake of 
calcium (g/day)
0.39±0.09 0.41±0.07 0.41
Average intake of 
Vitamin D (IU/day)
138.65±53.03 172.81±49.33 0.001
Sunlight exposure 
(Min*m2/day)
4±0.86 6.14±1.58 <0.001
Serum calcium 
(mg/dl)
9.32±0.42 9.43±0.42 0.12
Serum phosphorus 
(mg/dl) 
4.31±0.6 4.81±0.8 <0.001
Serum alkaline 
phosphatase (IU/l)
307.44±150.63 251.29±78.95 0.06
Serum Vitamin D 
(ng/dl)
18.24±11.2 31.58±17.31 <0.001
Serum PTH (pg/ml) 74.49±107.73 41.48±54.48 0.02
CLHIV: Children living with HIV, PTH: Parathyroid hormone
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inadequate dietary intake, lack of dietary supplementation of 
Vitamin D, and dark skin color. However, a similar prevalence was 
observed in a study published in the Western world. Kakalia et al. 
reported only 15% of the subjects with sufficient Vitamin D levels 
(>75 nmol/L) and the authors attributed this to possible poor sunlight 
exposure, sunscreen use, and poor dietary intake [17]. One study 
that evaluated the nutritional status of CLHIV from Southern India 
reported the prevalence of VDD to be 51.9% [20].
This study also observed a significantly lower serum Vitamin D 
levels in CLHIV in comparison to controls. This might be due to 
the disparity observed in the nutritional status of the two groups. 
A statistically significant difference was observed between the 
two groups with regard to an average intake of Vitamin D and 
sunlight exposure. This could be due to the presence of commonly 
occurring comorbidities in CLHIV that hamper adequate dietary 
intake. Furthermore, CLHIV are more likely to be less physically 
active than controls, hence having lesser sunlight exposure. 
The study by Rutstein et al. too observed a significantly lower 
Vitamin D levels among cases in comparison to controls [16].
However, many studies failed to report any significant difference 
in Vitamin D levels between HIV-positive subjects and controls [15]. 
Meyzer et al. reported a significantly higher mean level of 
Vitamin D in HIV-infected children than controls [11]. These results 
were attributed to the higher rates of Vitamin D supplementation in 
the HIV-infected group. Our study did not observe any correlation 
between Vitamin D status and ART. This could be due to the 
majority of our subjects being on nevirapine which in comparison 
to efavirenz caused less induction of cytochrome enzyme [21].
There were few limitations of the study. It failed to find any 
correlation between Vitamin D and the CD4 count, as reported in 
other studies [18,19]. The correlation of Vitamin D levels with 
viral load could not be done in CLHIV as this facility due to a lack 
of availability and cost involved. Another limitation of this study 
is that the effects of season and skin color on Vitamin D levels 
were not assessed. It was observed that the poor intake of Vitamin 
D significantly predicted the presence of VDD. This observation 
reinforced the importance of dietary intake of Vitamin D for the 
maintenance of adequate serum levels.
CONCLUSION
VDD is an important and frequently ignored comorbidity seen 
in Indian CLHIV. As it may lead to potentially severe acute and 
long-term consequences on skeletal as well as extra-skeletal 
functions, there is an urgent need to develop guidelines for 
screening, supplementing, and monitoring for VDD in CLHIV 
more so for developing countries.
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